Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × dabrafenib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 30 Neoplasms 18 Carcinoma, Non-Small-Cell Lung 7 Skin Neoplasms 4 Neoplasm Metastasis 4 Glioma 4 Brain Neoplasms 4 Thyroid Carcinoma, Anaplastic 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurocytoma 2 Lung Neoplasms 2 Glioblastoma 2 Ganglioneuroma 2 Ganglioglioma 2 Astrocytoma 2 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Nonseminomatous germ cell tumor 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neuroblastoma 1 Multiple Myeloma 1 Melanoma, Cutaneous Malignant 1 Leukemia, Hairy Cell 1 Histiocytosis, Langerhans-Cell 1 Gastrointestinal Stromal Tumors 1 Fever 1 Differentiated Thyroid Cancer (DTC) 1

Interventions

Dexamethasone 53 Lenalidomide 29 Cyclophosphamide 29 pomalidomide 27 Rituximab 27 Bortezomib 24 venetoclax 23 fludarabine 21 Paclitaxel 19 carfilzomib 18 Gemcitabine 18 Cisplatin 15 Carboplatin 15 pembrolizumab 14 daratumumab 14 Docetaxel 12 Calcium Dobesilate 12 Azacitidine 12 obinutuzumab 11 ibrutinib 11 Cytarabine 11 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 Injections 9 durvalumab 8 cemiplimab 8 blinatumomab 8 Doxorubicin 8 Cetuximab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡